摘要
目的探讨乌灵胶囊对脑卒中后抑郁患者有效性和安全性的影响。方法选取浙江省乐清市第三人民医院于2012年7月~2014年9月期间所收治的90例脑卒中后抑郁患者作为研究对象,采用随机数字表法将其分为治疗组(45例)和对照组(45例)。对照组脑卒中后抑郁患者采用西药氟西汀的临床药物治疗方案,而治疗组脑卒中后抑郁患者则采用中药乌灵胶囊的临床药物治疗方案,6周为1个疗程,均治疗2个疗程后分别对2组患者的临床指标改善效果、临床治疗效果、细胞因子变化、不良反应发生率进行比较和分析。结果治疗组治疗后的汉密顿抑郁量表(Hamilton depression scale,HAMD)评分值和日常生活活动量表(Barther index,BI)评分值均明显优于对照组(P<0.05);治疗组的临床显效率和总有效率均显著高于对照组(P<0.05);治疗组治疗后的细胞因子白细胞介素-6(interleukin-6,IL-6)和肿瘤坏死因子-α(tumor necrosis factor-α,TNF-α)明显低于对照组(P<0.05);与对照组相比,治疗组不良反应发生率显著降低(P<0.05)。结论乌灵胶囊提升脑卒中后抑郁患者的临床疗效,改善不良反应均具有一定的治疗优势,推荐其为脑卒中后抑郁患者的首选治疗药物。
Objective To explore the effect on efficacy and safety of Wuling capsule on patients with post-stroke depression.Methods From July 2012 to September 2014, 90 post-stroke depression patients were selected in our hospital.The patients were divided into treatment group (n=45) and control group (n=45) by random number table method.The post-stroke depression patients in control group were treated with fluoxetine as clinical drug program.The post-stroke depression patients in treatment group were treated with Wuling capsule as clinical drug program, six weeks for a course of treatment, both group were treated after two courses,the clinical indicators improve effect, clinical treatment, changes of cytokines, incidence of adverse reactions of the patients between two groups were compared and analyzed.Results Hamilton depression scale (HAMD) scores and Barther index (BI) scores of patients in treatment group post-treatment were better than control group (P<0.05) .Compared with control group, the ratio of clinical efficiency and total efficiency significant in treatment group were increased significantly (P<0.05).The patients in treatment group post-treatment, the levels of cytokine of interleukin-6 (IL-6) and tumor necrosis factor-α(TNF-α) decreased significantly (P<0.05) .Compared with control group, the incidences of adverse effect of patients in treatment group were decreased (P<0.05).Conclusions Wuling capsule has certain therapeutic advantages for improving clinical efficacy and reducing adverse reactions for patients with post-stroke depression.It could as the therapy of choice for post-stroke depression patients.
出处
《中国生化药物杂志》
CAS
2015年第10期29-31,共3页
Chinese Journal of Biochemical Pharmaceutics
